ArticleFrontiers in physiology2026
Clinical and histopathological predictors of secondary arteriovenous fistula failure due to intimal hyperplasia.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intimal hyperplasia (IH) is an important pathological mechanism underlying secondary arteriovenous fistula (AVF) failure in previously mature fistulas, yet the clinical and histopathological determinants that distinguish progressive IH leading to access loss from stable IH remain poorly characterized. This study aimed to identify clinical and histopathological predictors of secondary AVF failure due to IH in previously mature fistulas, and to develop a predictive nomogram for risk stratification. Methods: This retrospective cohort study enrolled 320 patients with end-stage renal disease (ESRD) who underwent AVF creation between January 2020 and June 2025 and had histopathologically confirmed IH from surgical specimens. Patients were classified into a secondary failure group (n = 142, previously mature AVFs permanently abandoned due to IH-driven dysfunction) and a secondary patency group (n = 178) based on access outcomes. Clinical, laboratory, hemodynamic, and histopathological variables were compared between groups. Multivariable logistic regression was performed to identify independent predictors. A nomogram was constructed and internally validated using bootstrap resampling (1,000 iterations). Results: Multivariable analysis identified seven independent predictors of secondary AVF failure: diabetes mellitus (OR = 2.31, 95% CI: 1.42-3.76, P = 0.001), C-reactive protein ≥ 8.0 mg/L (OR = 1.89, 95% CI: 1.18-3.03, P = 0.008), intima-to-media thickness ratio > 1.5 (OR = 3.67, 95% CI: 2.18-6.17, P < 0.001), CD68 Conclusions: Integration of clinical parameters and histopathological markers enables accurate prediction of secondary AVF failure due to IH. The proposed nomogram may facilitate individualized risk stratification and guide clinical decision-making regarding vascular access management in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.